Disease · MONDO_0007488

Lewy body dementia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Lewy body dementia. Diseases, record MONDO_0007488. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0007488

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Lewy body dementia; Open Targets
Open Targets ID: MONDO_0007488; Open Targets
Other names: DLB, Lewy body disease, cortical Lewy body disease, dementia with Lewy bodies, lewy body dementia, susceptibility to; Open Targets
Disease Ontology: DOID:12217; Disease Ontology
NCI Thesaurus: C84826; NCI Thesaurus
Orphanet: ORPHA:1648; Orphanet
Highest stage of its drugs: Approval, for 1 of its 21 drugs, from EMA Human Drugs; Open Targets

Drugs21

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
IOFLUPANE I 123	CHEMBL3989517	Small molecule	Approval	EMA Human Drugs	1	0	0	Drugs and targets
DONEPEZIL	CHEMBL502	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
GALANTAMINE	CHEMBL659	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
DONEPEZIL HYDROCHLORIDE	CHEMBL1678	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
NEFLAMAPIMOD	CHEMBL119385	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
NILOTINIB	CHEMBL255863	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
TERAZOSIN	CHEMBL611	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
IRSENONTRINE	CHEMBL4650368	Small molecule	Phase 2	ClinicalTrials.gov and TTD	3	1	1	Drugs and targets
BOSUTINIB	CHEMBL288441	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CLENBUTEROL	CHEMBL49080	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 21

See all 21 drugs

Targets18

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ACHE	Acetylcholinesterase	4	Acetylcholinesterase inhibitor; Cholinesterases; ACHE & BCHE inhibitor	Phase 3	https://conductscience.org/library/genes/43	Drugs and targets
ABL1	Bcr/Abl fusion protein	2	Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor	Phase 2	https://conductscience.org/library/genes/25	Drugs and targets
ADRA1A	Adrenergic receptor alpha-1	2	Adrenergic receptor alpha-1 antagonist	Phase 2	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1B	Adrenergic receptor alpha-1	2	Adrenergic receptor alpha-1 antagonist	Phase 2	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor alpha-1	2	Adrenergic receptor alpha-1 antagonist	Phase 2	https://conductscience.org/library/genes/146	Drugs and targets
ADRB2	Beta-2 adrenergic receptor	2	Beta-2 adrenergic receptor agonist; Beta-2 adrenergic receptor antagonist	Phase 2	https://conductscience.org/library/genes/154	Drugs and targets
BCR	Bcr/Abl fusion protein	2	Bcr/Abl fusion protein inhibitor	Phase 2	https://conductscience.org/library/genes/613	Drugs and targets
ADRB1	Beta-1 adrenergic receptor	1	Beta-1 adrenergic receptor antagonist	Phase 2	https://conductscience.org/library/genes/153	Drugs and targets
BCHE	Cholinesterases; ACHE & BCHE	1	Cholinesterases; ACHE & BCHE inhibitor	Unknown	https://conductscience.org/library/genes/590	Drugs and targets
HCK	Tyrosine-protein kinase HCK	1	Tyrosine-protein kinase HCK inhibitor	Phase 2	https://conductscience.org/library/genes/3055	Drugs and targets

1 to 10 of 18

See all 18 targets

Trials22

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00543855	A Double-blind Study of E2020 (Donepezil Hydrochloride) in Patients With Dementia With Lewy Bodies (DLB) (Study E2020-J081-431)	Phase 2	167	2013-02-18	Dementia With Lewy Bodies (DLB)	DONEPEZIL HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT00598650	A Long-term, Extension Study of E2020 in Patients With Dementia With Lewy Bodies	Phase 2	160	2014-09-03	Dementia With Lewy Bodies (DLB)	DONEPEZIL HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT01278407	A Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase	Phase 3	142	2015-11-30	Dementia With Lewy Bodies (DLB)	DONEPEZIL	Its record names the disease	ClinicalTrials.gov
NCT04001517	Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies	Phase 2	91	2021-11-02	Dementia With Lewy Bodies (DLB)	NEFLAMAPIMOD	Its record names the disease	ClinicalTrials.gov
NCT04739423	A Study of Clenbuterol (CST-103) Co-administered With Nadolol (CST-107) in Subjects With Neurodegenerative Disorders	Phase 2	41	2024-12-02	Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease Dementia	CLENBUTEROL, NADOLOL	Its record names the disease	ClinicalTrials.gov
NCT04764669	A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology	Phase 2	34	2022-09-26	Lewy Body Disease, Parkinson Disease	IRSENONTRINE	Its record names the disease	ClinicalTrials.gov
NCT02448784	Post-marketing Surveillance of Donepezil Hydrochloride - Investigation of Long Term Safety and Efficacy of Aricept as Well as Its Proper Use Information in Patients With Dementia With Lewy Bodies (DLB).		591		Dementia With Lewy Body Disease	DONEPEZIL HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT05869669	RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies	Phase 2	159		Dementia With Lewy Bodies	NEFLAMAPIMOD	Its record names the disease	ClinicalTrials.gov
NCT07464028	Terazosin And Metabolic Energetics in Parkinson's Disease	Phase 2	120		Parkinson's Disease (PD)	TERAZOSIN	Its record names the disease	ClinicalTrials.gov
NCT04148391	NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)	Phase 2	99		Mild Cognitive Impairment, Mild Dementia, Parkinson Disease, Lewy Body Disease	NEVADISTINEL	Its record names the disease	ClinicalTrials.gov

1 to 10 of 22

See all 22 trials

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials13

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
27434297	RESULT	2	PubMed
25635231	RESULT	1	PubMed
23666528	RESULT	1	PubMed
14676468	RESULT	1	PubMed
40680102	DERIVED	1	PubMed
38706271	DERIVED	2	PubMed
37657939	DERIVED	1	PubMed
36130946	DERIVED	1	PubMed
34786477	DERIVED	1	PubMed
32346907	DERIVED	1	PubMed

1 to 10 of 13

See all 13 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0007488

GET https://conductscience.org/api/diseases/v1/MONDO_0007488/drugs?page=2

API reference For AI assistants